TABLE 5.
Mean changes (Δ) from baseline in serum electrolyte and creatinine levels
| Parameter | Colonoscopy preparation group | P | |||
|---|---|---|---|---|---|
| 4L PEG (n=117) | 2L PEG + B (n=135) | NaP (n=99) | PSMC + M (n=129) | ||
| ΔNa, mmol/L | 1.87 | 2.51 | 2.05 | 2.48 | 0.011 |
| Serum Na | 1 (0.6) | 0 (0) | 0 (0) | 1 (0.6) | 0.332 |
| >145 mmol/L*, n (%) | |||||
| ΔK, mmol/L | 0.74 | 0.65 | 0.80 | 0.57 | <0.0001 |
| Serum K | 1 (0.6) | 0 (0) | 11 (11) | 1 (0.6) | <0.0001 |
| <3.0 mmol/L*, n (%) | |||||
| ΔCl, mmol/L | 2.85 | 3.14 | 3.77 | 3.41 | 0.61 |
| ΔCa, mmol/L | 0.075 | 0.089 | 0.081 | 0.084 | 0.259 |
| Serum Ca | 21 (18) | 9 (7) | 25 (25) | 7 (5) | <0.0001 |
| <2.2 mmol/L*, n (%) | |||||
| ΔPO4, mmol/L | 0.17 | 0.16 | 0.36 | 0.18 | <0.001 |
| Serum PO4 | 0 (0) | 0 (0) | 6 (6) | 0 (0) | <0.0001 |
| >2.0 mmol/L*, n (%) | |||||
| ΔCreatinine, μmol/L | 9.04 | 9.32 | 7.52 | 9.96 | 0.074 |
| Rise in creatinine | 2 (2) | 4 (3) | 1 (1) | 6 (5) | 0.0681 |
| ≥20 μmol/L*, n (%) | |||||
*
Abnormal laboratory value. B Bisacodyl; M Magnesium citrate; NaP Sodium phosphate; PEG Polyethylene glycol; PSMC Pico-Salax (Ferring Pharmaceuticals Inc, Canada)